Abstract
α4β7 is a prototypic gut integrin that regulates homing of memory and effector T cells to the gut.1 Vedolizumab is an anti-α4β7 monoclonal antibody and is approved by the US Food and Drug Administration to treat ulcerative colitis and Crohn disease (CD).1.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
